Holder A A
Division of Parasitology, MRC National Institute for Medical Research, The Ridgeway, Mill Hill, London.
Parasitology. 2009 Oct;136(12):1445-56. doi: 10.1017/S0031182009990515. Epub 2009 Jul 23.
Over the last 30 years, evidence has been gathered suggesting that merozoite surface protein 1 (MSP1) is a target of protective immunity against malaria. In a variety of experimental approaches using in vitro methodology, animal models and sero-epidemiological techniques, the importance of antibody against MSP1 has been established but we are still finding out what are the mechanisms involved. Now that clinical trials of MSP1 vaccines are underway and the early results have been disappointing, it is increasingly clear that we need to know more about the mechanisms of immunity, because a better understanding will highlight the limitations of our current assays and identify the improvements required. Understanding the structure of MSP1 will help us design and engineer better antigens that are more effective than the first generation of vaccine candidates. This review is focused on the carboxy-terminus of MSP1.
在过去30年里，已有证据表明裂殖子表面蛋白1（MSP1）是疟疾保护性免疫的靶点。在使用体外方法、动物模型和血清流行病学技术的各种实验方法中，抗MSP1抗体的重要性已得到证实，但我们仍在探究其中涉及的机制。鉴于MSP1疫苗的临床试验正在进行，且早期结果令人失望，越来越明显的是，我们需要更多地了解免疫机制，因为更好的理解将凸显我们当前检测方法的局限性，并确定所需的改进之处。了解MSP1的结构将有助于我们设计和构建比第一代候选疫苗更有效的更好抗原。本综述聚焦于MSP1的羧基末端。
